Global Point-of-care Testing

Global Point-of-care Testing

The global point-of-care testing market is expected to witness a compound annual growth rate (CAGR) of 5.8% during the forecast period, reaching a projected value of USD 24,161 million by 2029.

The market size spans various therapy areas, including infectious diseases, diabetes and endocrine disorders, cardiovascular conditions, and others. According to Tanalyze's estimates, within the infectious diseases segment, the market size is projected to exhibit a CAGR of 4.9% from 2024 to 2029.

This report provides an analysis of the global point-of-care testing market segmentation by care continuum for the forecast period. Key segments within the care continuum include clinical settings and alternative settings.

The clinical settings segment has shown significant growth, with a compound annual growth rate (CAGR) of 5.2% anticipated from 2024 to 2029.

Geographically, North America emerged as the dominant player in the point-of-care testing market in 2023, followed closely by Europe and the Asia-Pacific region. Looking ahead, the market size in the Asia-Pacific sector is expected to expand further, with an anticipated CAGR of 7.0% from 2024 to 2029, highlighting the region's continued growth prospects and demand.

Prominent vendors shaping the competitive landscape include Abbott Laboratories, Roche Holding AG, QuidelOrtho Corporation, Danaher Corporation, Siemens Healthineers AG, BioMérieux SA, Cue Health Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Sysmex Corporation, LumiraDx Ltd., and Becton, Dickinson and Company (BD), among others.

This study aims to analyze the global market for various segments of point-of-care testing, including:

Therapy Areas: Infectious Diseases, Diabetes and Endocrine, Cardiovascular, and Others.

Care Continuum: Clinical Settings and Alternative Settings.

Test Type: Immunochemistry and Molecular.

Region: North America, Europe, Asia-Pacific, and Rest of World (RoW).